每經AI快訊,近日,成都紐瑞特醫療科技股份有限公司(簡稱“紐瑞特”)獲上市輔導備案登記,擬在A股IPO,輔導機構為國泰海通。該公司從事醫用同位素和放射性藥品研發。
特別聲明:以上內容(如有圖片或視頻亦包括在內)為自媒體平臺“網易號”用戶上傳并發布,本平臺僅提供信息存儲服務。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.